

Biosimilars in Oncology: Potential Value for Practices, Hospitals, and Healthcare Systems



US Costs in Oncology


- Total spending on US cancer care is **projected to rise 34%** from 2015–2030¹
- **Financial management remains the #1 concern** of surveyed hospital CEOs²
- Biosimilars **help reduce costs in oncology**, as they have been associated with \$37 billion in savings **across all therapeutic areas where they have been introduced (e.g., inflammation, supportive care, and oncology)** since the passage of the Biosimilars Act in 2010. Biosimilars are projected to produce an estimated \$104 billion in savings from 2020–2024³⁻⁵

20✓



Impact of Oncology Biosimilars

- There are currently **20 approved biosimilars** covering 3 oncology therapeutic antibodies and 3 supportive care agents as of May 2022^{6,7}
- **Biosimilar alternatives are available** for 4 of the top 5 most costly oncology and supportive care **medical benefit** drugs for commercially covered patients, and 4 of the top 6 most costly **oncology and supportive care medical benefit** drugs for patients on Medicare⁸
- Increased biosimilar competition has led to **decreased price for every therapeutic agent** in oncology and supportive care where biosimilars are available^{9,10}
 - Oncology therapeutic antibodies: As of 1Q2022, 32%–46% below originator ASP from the time biosimilar was launched⁹
 - Supportive care: As of 1Q2022, 37%–51% below originator ASP from the time biosimilar was launched⁹
- Oncology biosimilars have had **greater and more rapid uptake** than other biosimilars³
 - Oncology therapeutic antibodies are tracking toward nearly 60% market uptake in the first 2 years of availability³



ASP=average selling price.



Pfizer's Heritage in Biosimilars

- Pfizer has the **largest oncology biosimilar portfolio in the market** to provide more treatment options to more patients, and is committed to supporting these options for the US healthcare system¹¹
- Pfizer is quality focused, with all biosimilars produced to meet the **same high-quality standards as its biologics**⁹

Pfizer Provides Support to Help With Seamless Biosimilar Integration

Resources are available to help practices, hospitals, and health systems integrate biosimilars through effective operational enablement, IT, monitoring, education, and communication



EHR=electronic health record; IT=information technology; P&T=pharmacy and therapeutics committee.

For more information, please speak with your Pfizer representative and visit [PfizerBiosimilars.com](https://www.pfizer.com/biosimilars)

References: **1.** Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States *Cancer Epidemiol Biomarkers Prev.* 2020;29(7):1304-1312. **2.** American College of Healthcare Executives. Survey: healthcare finance, personnel shortages, behavioral health/addiction issues cited by CEOs as top issues confronting hospitals in 2019. <https://www.ache.org/about-ache/news-and-awards/news-releases/top-issues-confronting-hospitals-in-2019>. Updated March 2, 2020. Accessed June 28, 2022. **3.** IQVIA. Biosimilars in the United States 2020-2024. <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024>. Updated September 29, 2020. Accessed June 28, 2022. **4.** US Food and Drug Administration. Biosimilars. <https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars>. Updated March 8, 2022. Accessed June 28, 2022. **5.** Brougher JT. The Biosimilars Act: Promoting or Discouraging the Development of Generic Biologics?: A tug-of-war between generic and innovator biologics seems to be where drug developers are headed. *Biotechnol Healthc.* 2010;7(4):22-23. **6.** Biehn B, Nell C; AmerisourceBergen. US Biosimilar Report. <https://www.amerisourcebergen.com/-/media/assets/amerisourcebergen/biosimilars-page/sgs-biosimilars-usmarketlandscape-053122.pdf>. Updated May 27, 2022. Accessed June 28, 2022. **7.** US Food and Drug Administration. Biosimilar product information. <https://www.fda.gov/drugs/biosimilars/biosimilar-product-information>. Updated May 2022. Accessed June 28, 2022. **8.** Magellan Rx Management. Medical Pharmacy Trend Report™, 2020. 11th edition. <https://www1.magellanrx.com/read-watch-listen/read/our-publications/medical-pharmacy-trend-report/>. Accessed June 28, 2022. **9.** Data on file. Pfizer Inc., New York, NY. **10.** Greene L, Singh RM, Carden MJ, Pardo CO, Lichtenstein GR. Strategies for overcoming barriers to adopting biosimilars and achieving goals of the Biologics Price Competition and Innovation Act: a survey of managed care and specialty pharmacy professionals. *J Manag Care Spec Pharm.* 2019;25(8):904-912. **11.** Drugs.com. How many biosimilars have been approved in the United States? <https://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/>. Updated May 31, 2022. Accessed June 28, 2022.